- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AA-673 | Amlexanox® | Aphthasol® | CHX-3673
amlexanox is an approved drug (FDA (1996))
Compound class: Synthetic organic
Comment: Amlexanox has anti-inflammatory , antiallergic and immunomodulatory actions . Proposed to inhibit IKKδ and TBK1, albeit with low potency .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Bell J. (2005)
Amlexanox for the treatment of recurrent aphthous ulcers.
Clin Drug Investig, 25 (9): 555-66. [PMID:17532700]
2. Elad S, Epstein JB, von Bültzingslöwen I, Drucker S, Tzach R, Yarom N. (2011)
Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents.
Expert Opin Emerg Drugs, 16 (1): 183-202. [PMID:21244328]
3. Makino H, Saijo T, Ashida Y, Kuriki H, Maki Y. (1987)
Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.
Int Arch Allergy Appl Immunol, 82 (1): 66-71. [PMID:2433225]
4. Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang SH, Chang L, Saltiel AR. (2013)
Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Elife, 2: e01119. DOI: 10.7554/eLife.01119 [PMID:24368730]
5. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I et al.. (2013)
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Nat Med, 19 (3): 313-21. [PMID:23396211]
6. Spina D. (2008)
PDE4 inhibitors: current status.
Br J Pharmacol, 155 (3): 308-15. [PMID:18660825]